16.02.2018 • NewsAlzheimerDede WillamsMerck & Co.

US Merck Discontinues Alzheimer’s Drug Trial

Merck & Co. has said it will halt its APECS Phase 3 clinical trial evaluating...
Merck & Co. has said it will halt its APECS Phase 3 clinical trial evaluating the efficacy and safety of verubecestat MK-8931 in people with prodromal Alzheimer’s disease (c) Alexander Raths/Shutterstock

US drugmaker Merck & Co. has said it will halt its APECS randomized, placebo-controlled, parallel-group, double-blind Phase 3 clinical trial evaluating the efficacy and safety of verubecestat MK-8931 in people with prodromal Alzheimer’s disease (AD).

MK-8931 is an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).

The company known outside the US as MSD said the decision to stop the study follows a recommendation by the external Data Monitoring Committee (eDMC), which assessed the overall benefit/risk during a recent interim safety analysis. Merck said the eDMC concluded it was unlikely that a positive benefit/risk could be established if the trial continued.

The US drugmaker said the data from the study will be presented at an upcoming medical meeting.

Merck became the second within days to reveal the lack of success in an advanced clinical trial with a hitherto promising Alzheimer’s candidate. Germany’s Boehringer Ingelheim said earlier this week it planned to shift the focus of its investigational compound BI 409306 to ongoing clinical trials with schizophrenia patients after the drug failed to outperform a placebo in Phase II trials with 450 patients for the indication Alzheimer's.

Commenting on the US company’s problems, Roger M. Perlmutter, president of Merck Research Laboratories, said Merck remains committed to developing novel therapies for the treatment of Alzheimer’s and other neurodegenerative diseases.”

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.